Edition:
United States

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

5.53USD
19 Oct 2018
Change (% chg)

$-0.05 (-0.90%)
Prev Close
$5.58
Open
$5.57
Day's High
$5.62
Day's Low
$5.41
Volume
48,753
Avg. Vol
80,858
52-wk High
$6.96
52-wk Low
$2.02

Latest Key Developments (Source: Significant Developments)

Adma Biologics Provides Regulatory Update For Bivigam
Thursday, 11 Oct 2018 08:48am EDT 

Oct 11 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS PROVIDES REGULATORY UPDATE FOR BIVIGAM®.ADMA BIOLOGICS INC - FDA HAS ESTABLISHED A TARGET ACTION DATE OF DECEMBER 18, 2018 FOR PAS UNDER PRESCRIPTION DRUG USER FEE ACT.ADMA BIOLOGICS - FDA CONSIDERS CO'S RECENT RESPONSE TO AGENCY'S INFORMATION REQUEST RELATED TO PRIOR APPROVAL SUPPLEMENT SUBMISSION A MAJOR AMENDMENT.ADMA BIOLOGICS - FDA COMMUNICATION RECEIVED BY CO HAS NO IMPACT ON OTHER ONGOING AGENCY INTERACTIONS OR TO RECENT RI-002 BLA RESUBMISSION.ADMA BIOLOGICS - FDA HAS INFORMED CO THAT THEY REQUIRE MORE 2 MONTHS TO COMPLETE THEIR REVIEW OF PAS SUBMITTED IN JUNE 2018 TO AMEND BLA FOR BIVIGAM.  Full Article

ADMA Biologics Reports FDA Compliance Status For Manufacturing Facility
Wednesday, 5 Sep 2018 07:08am EDT 

Sept 5 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS FDA COMPLIANCE STATUS FOR ITS MANUFACTURING FACILITY HAS IMPROVED.ADMA BIOLOGICS INC - RI-002'S BIOLOGICS LICENSE APPLICATION RESUBMISSION TARGETED FOR Q3 2018.ADMA BIOLOGICS INC - FDA INSPECTION DATABASE CONFIRMS VAI STATUS OF BOCA RATON, FL FACILITY.ADMA BIOLOGICS INC - WILL ANNOUNCE RELATED INFORMATION PERTAINING TO RI-002'S BLA FILING WHEN COMPANY RECEIVES CORRESPONDENCE FROM FDA.  Full Article

ADMA Biologics Q1 Loss Per Share $0.39
Monday, 14 May 2018 05:05pm EDT 

May 14 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.39.Q1 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.Q1 REVENUE ROSE 54 PERCENT TO $4.0 MILLION.Q1 REVENUE VIEW $6.2 MILLION -- THOMSON REUTERS I/B/E/S.ADMA BIOLOGICS - AT MARCH 31, 2018, ADMA HAD CASH AND CASH EQUIVALENTS OF $26.1 MILLION, AS COMPARED TO $43.1 MILLION AT DECEMBER 31, 2017.  Full Article

ADMA Biologics Retires About 8.6 Million Shares Previously Issued to Biotest
Monday, 14 May 2018 01:16pm EDT 

May 14 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS INC - RETIRES APPROXIMATELY 8.6 MILLION SHARES PREVIOUSLY ISSUED TO BIOTEST PHARMACEUTICALS CORPORATION AND ITS FORMER PARENT, BIOTEST AG.ADMA BIOLOGICS - BPC WILL TRANSFER ABOUT 8.6 MILLION SHARES OF ADMA'S NON-VOTING COMMON STOCK BACK TO ADMA.ADMA BIOLOGICS - RETIREMENT OF ABOUT 8.6 MILLION SHARES FOR WAIVER AND RELEASE OF CERTAIN ADMA RIGHTS UNDER AGREEMENT, DATED AS OF JANUARY 21, 2017.ADMA BIOLOGICS INC - BPC WILL WAIVE AND TERMINATE ALL RIGHTS TO NAME A DIRECTOR AND OBSERVER TO ADMA'S BOARD OF DIRECTORS.ADMA BIOLOGICS - ADMA WILL TERMINATE RIGHTS TO REPURCHASE 2 ADMA BIOCENTERS WHICH CO HAD PREVIOUSLY AGREED TO TRANSFER TO BPC ON JANUARY 1, 2019..  Full Article

ADMA Biologics Releases Its First Commercial Batch Of Nabi-HB Manufactured Under Its Ownership
Tuesday, 24 Apr 2018 07:28am EDT 

April 24 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ANNOUNCES THE RELEASE OF ITS FIRST COMMERCIAL BATCH OF NABI-HB MANUFACTURED UNDER ITS OWNERSHIP.ADMA BIOLOGICS INC - COMPLETED MANUFACTURING, RELEASE AND HAS MADE COMMERCIAL SALES OF ITS FIRST BATCH OF NABI-HB.  Full Article

Adma Biologics Reports FY'17 Financial Results
Monday, 5 Mar 2018 07:00am EST 

March 5 (Reuters) - Adma Biologics Inc ::ADMA BIOLOGICS REPORTS FULL YEAR 2017 FINANCIAL RESULTS.ADMA BIOLOGICS - ‍BELIEVE PROGRESS MADE WITH COMPLIANCE ENHANCEMENT PROGRAM ALLOWED REMEDY OF IDENTIFIED COMPLIANCE ISSUES AT BOCA FACILITY​.ADMA BIOLOGICS - ‍BELIEVE CO NOW READY FOR ROUTINE INSPECTION OF BOCA FACILITY BY U.S. FDA.ADMA BIOLOGICS - ‍AT DEC 31, 2017, HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS OF $43.1 MILLION, VERSUS $15.3 MILLION AT DEC 31, 2016​.  Full Article

Adma Biologics prices follow-on offering of 17.0 mln shares
Thursday, 9 Nov 2017 08:58am EST 

Nov 9 (Reuters) - Adma Biologics Inc :Adma Biologics announces pricing of follow-on offering.Adma Biologics Inc - ‍pricing of offering of approximately 17.0 million shares of its common stock at price of $2.15 per share​.  Full Article

ADMA Biologics now sees offering‍​ of 13.6 mln shares of common stock - SEC filing
Wednesday, 8 Nov 2017 03:38pm EST 

Nov 8 (Reuters) - ADMA Biologics Inc ::Now sees offering‍​ of 13.6 million shares of its common stock, up from previous filing of 10.2 million shares - SEC filing.  Full Article

ADMA Biologics Q3 loss per share $0.59
Friday, 3 Nov 2017 05:02pm EDT 

Nov 3 (Reuters) - ADMA Biologics Inc ::ADMA Biologics provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.59.Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Q3 revenue rose 61 percent to $4.7 million.Q3 revenue view $6.5 million -- Thomson Reuters I/B/E/S.  Full Article

ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30​
Friday, 3 Nov 2017 04:58pm EDT 

Nov 3 (Reuters) - Adma Biologics Inc :ADMA Biologics Inc says ‍for fiscal quarter ended September 30, loss per share was $0.59 - SEC filing​.ADMA Biologics Inc - qtrly total revenues $4.7 million versus $2.9 million ‍​.  Full Article

BRIEF-ADMA Biologics Files For Mixed Shelf Offering Of Up To $100 Mln

* ADMA BIOLOGICS FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source http://bit.ly/2IrSugh Further company coverage: